Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases.

Chemoradiotherapy followed by consolidative immunotherapy is the standard-of-care for unresectable stage III non-small cell lung cancers (NSCLC), yet confers limited benefit in those with driver mutations, BRAF-V600x included. Here, we report two cases of unresectable stage III NSCLC harboring BRAF V600E mutation treated with induction dabrafenib, trametinib, and a PD-1 inhibitor. Both patients exhibited significant tumor regression, enabling surgical conversion and achieving pathological complete or major response, without significant adverse events. These cases suggest that targeted-immunotherapy combinations may present a promising treatment option for tumor downstaging and surgical conversion in unresectable stage III NSCLC with BRAF V600E mutation. However, prospective studies with larger cohorts and longer follow-up are warranted to validate this strategy.